Alpine’s data room was the most exclusive club in biotech. Then Vertex became the VIP

After Alpine Immune Sciences presented initial data for the kidney disease therapy povetacicept at a conference in November 2023, the biotech’s confidential data room became the most exclusive club in biotech.

Four unnamed companies, plus Vertex Pharmaceuticals, already had confidentiality agreements in place with the autoimmune and inflammatory disease biotech at the time of the data reveal, according to regulatory documents posted Monday. But Vertex would ultimately prevail, buying Alpine for $4.9 billion on April 10.

Alpine showed that low-dose povetacicept improved proteinuria in patients with IgA nephropathy (IgAN) in a poster session at the American Society of Nephrology Kidney Week conference on Nov. 2, setting off a hot pursuit for a deal.

The company moved to get a phase 3 test of povetacicept underway, while executives fielded calls from interested companies hoping to learn more about the development plan. Data rooms were set up, but the documents…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks